We use cookies to deliver our online services. Details of the cookies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you agree to our use of cookies. To close this message click close.
Life Sciences and Healthcare frame

Life Sciences and Healthcare

Navigating complexities in the life sciences and healthcare industries is no easy task. Successfully competing in the space requires a partner with a holistic, collaborative approach and a global perspective. It calls for a strategy informed by asking the right questions and rooted in identifying creative solutions to your unique challenges.

For life sciences innovators of all sizes, anywhere in the world, Hogan Lovells is that partner — from cutting-edge start-ups and boutique venture funds to world-renowned research institutions and health systems to global biopharmaceutical conglomerates.

Your business and your challenges don’t stop for oceans or disappear at national borders. Neither does Hogan Lovells. Our team of 450 life sciences lawyers is located around the world but operates as if everyone is working from the same office — providing a seamless experience everywhere you do business.

And no matter the challenge — from creation to commercialization of a life-saving therapy, regulatory compliance to an international patent dispute, the formation of a strategic alliance to a complex, global merger — we’ve been there before and we understand how to prepare you for what happens next, helping you to anticipate risks and address future issues before they arise.

Whatever your challenge, wherever the issue, Hogan Lovells has you covered. It’s that easy.

Hogan Lovells Publications

Brexit: first aid for Pharma - 19 July 2016

Brexit, if and when it happens, may have a substantial impact on the UK pharmaceutical industry. Although related issues will also have an impact upon many aspects of that industry, this...

Drug Pricing Myths and Realities

Beth Roberts argues that while profiteering stories get the bulk of the attention, the issue of drug pricing is much more complex.

Life Sciences Firms Particularly Vulnerable to Cyber Attack

Marcy Wilder recommends that firms consider five key factors when developing a security strategy.

Deal Structures in Life Sciences

Asher Rubin and Adam Golden say that the feverish pace of M&A acquisitions is likely to continue.

The Market for Biosimilars Is Growing

Phil Katz and Stephen Bennett discuss the differences in the biosimilar markets in the US and the U.K.

Representative Experience

Representing TESARO in its US$101m Series B financing, its IPO, and all of its follow-on equity financings and US$165m notes financing.

Advising a leading pharma company on its innovative approach regarding digital health offerings.

Global defense of TÜV Rheinland against liability claims resulting from allegedly inappropriate certification of breast implant manufacturer P.I.P.

Advising a drug company on strategies for obtaining orphan drug approval and working with scientific and regulatory groups to draft and submit designation request.

Advising a U.S. medical device company on regulatory and commercial issues regarding the market launch of a gene test in 24 European countries.

Advising MorphoSys AG in a worldwide license and collaboration agreement with Emergent Biosolutions to develop an antibody for the treatment of prostate cancer.

Handling hospital transactions for the University of Minnesota, Saint Louis University, Georgetown University, the University of Miami, the State University of New York, and more.

Instrumental in persuading FDA to change longstanding regulatory position on awarding exclusivity to fixed-dose combination products, benefitting Gilead’s products in the HIV and Hepatitis C fields.

Lead agency counsel for implementation of Affordable Care Act, including provisions governing health insurance coverage and Medicare Advantage plans.

Obtained a permanent injunction for a leading Japanese pharmaceutical firm in a bench trial on infringement and validity.

Representation of a global technology company in the creation of a joint venture to develop next-generation surgical robots.

Representing Allergan in the acquisition of rights to Ironwood Pharmaceuticals’ linaclotide product (CONSTELLA®) in more than 40 countries outside the U.S.

Representing Anthem, Inc. in more than 100 class action lawsuits that have been filed around the country related to their cyberattack. 


Representing Novartis in an exclusive global collaboration agreement with the University of Pennsylvania to develop and commercialize immunotherapies for cancer.

Representing Novartis in its landmark portfolio transformation transactions with GlaxoSmithKline and Eli Lilly valued at more than US$23bn.


Representing pharmaceutical and biologics companies in connection with numerous federal and state investigations of sales and marketing, pricing, Medicaid rebate, FDCA promotional issues, and cGMP compliance.

Representing provider networks in multiple investigations of their clinical integration and joint negotiations with health plans by federal and/or state antitrust enforcers.

Advising Lilly in its European patent disputes concerning its oncology product, pemetrexed.


2016

Ranked Band 1 for Life Sciences Global-wide

Chambers Global

2016

Ranked Band 1 for Life Sciences Europe-wide

Chambers Europe

2016

Leading law firm for Life Sciences with 40 individual listings

Who's Who Legal Life Sciences

2016

Healthcare Team of the Year

Chambers USA

2016

Awarded "Law Firm of the Year" for Pharmaceuticals Law in Germany

BestLawyers

2016

Ranked Band 1 for Healthcare - District of Columbia

Chambers USA

2016

Ranked Band 1 for Healthcare: Pharmaceutical/Medical Products Regulatory – District of Columbia

Chambers USA

2016

Ranked Band 1 for Life Sciences in Germany

Chambers Europe

2016

Ranked Band 1 for Life Sciences in Italy

Chambers Europe

2016

Ranked Band 1 for Life Sciences in The Netherlands

Chambers Europe

2015 & 2016

Ranked Band 1 for pharmaceutical and medical devices law in Germany

JUVE Handbook

2016

Ranked Band 1 for Healthcare and Life Sciences in The Netherlands

The Legal 500

2016

Ranked Band 1 for Healthcare and Life Sciences in France

The Legal 500

2016

Ranked Band 1 for Regulatory - Pharmaceuticals in Germany

The Legal 500

2016

Ranked Band 1 for Healthcare and Life Sciences in Italy

The Legal 500

Loading data